Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881695 | 0.93 | PPARG (0.51) | PPARGMCL1SNCAMAPTHDAC8 | |
| SCHEMBL5881578 | 0.92 | PPARG (0.55) | PPARGMCL1SNCAMAPTL3MBTL1 | |
| SCHEMBL5881789 | 0.91 | PPARG (0.54) | PPARGMCL1SNCAMAPTKDM4E | |
| SCHEMBL5881907 | 0.91 | PPARG (0.54) | PPARGMCL1SNCAMAPTKDM4E | |
| SCHEMBL5881856 | 0.91 | PPARG (0.47) | PPARGMCL1SNCAMAPTKLKB1 | |
| SCHEMBL5881939 | 0.89 | PTPN5 (0.43) | PPARGMCL1SNCAMAPTKLKB1 | |
| SCHEMBL5881878 | 0.88 | PPARG (0.41) | PPARGMCL1SNCAMAPTKLKB1 | |
| SCHEMBL5882225 | 0.87 | SNCA (0.41) | PPARGMCL1SNCAMAPTKLKB1 | |
| SCHEMBL5881794 | 0.87 | SNCA (0.46) | PPARGMCL1SNCAMAPTPTGS2 | |
| SCHEMBL5882877 | 0.85 | PPARG (0.51) | PPARGMCL1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1132087-A1 | REMEDIES FOR POLYCYSTIC OVARY SYNDROME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | IDO1, IDO2, INMT | PPARG 4239/4885MCL1 6/4885SNCA 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.